Nazione: Canada
Lingua: inglese
Fonte: Health Canada
EPOETIN ALFA
JANSSEN INC
B03XA01
ERYTHROPOIETIN
4000UNIT
SOLUTION
EPOETIN ALFA 4000UNIT
INTRAVENOUS
1ML
Prescription
HEMATOPOIETIC AGENTS
Active ingredient group (AIG) number: 0126696005; AHFS:
CANCELLED POST MARKET
2014-10-09
_/CurrentRegulatoryControlledLabellingDocuments/CPM/ENGLISH/eprex/EPR06222011CPM2.NC.doc _ _Page 1 of 73 _ PRODUCT MONOGRAPH PR EPREX ® * epoetin alfa Sterile Solution Single-use vials † : 1,000 IU/0.5 mL, 2,000 IU/mL, 4,000 IU/mL, 10,000 IU/mL, 40,000 IU/mL Single-use pre-filled syringes with PROTECS ®* needle guard: 1,000 IU/0.5 mL, 2,000 IU/0.5 mL, 3,000 IU/0.3 mL, 4,000 IU/0.4 mL, 5,000 IU/0.5 mL, 6,000 IU/0.6 mL, 8,000 IU/0.8 mL, 10,000 IU/mL, 20,000 IU/0.5 mL, 30,000 IU/0.75 mL, 40,000 IU/mL Erythropoiesis Regulating Hormone This Product Monograph is the exclusive property of Janssen Inc. It may not be copied in whole or in part without the written permission of Janssen Inc. Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 www.janssen.ca Date of Approval: October 14, 2011 Submission Control No: 145519 * All trademark rights used under license © 2011 JANSSEN Inc. _/CurrentRegulatoryControlledLabellingDocuments/CPM/ENGLISH/eprex/EPR06222011CPM2.NC.doc _ _Page 2 of 73 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 DESCRIPTION................................................................................................................... 3 INDICATIONS AND CLINICAL USE............................................................................. 4 CONTRAINDICATIONS .................................................................................................. 5 WARNINGS AND PRECAUTIONS................................................................................. 6 ADVERSE REACTIONS................................................................................................. 15 DRUG INTERACTIONS ................................................................................................. 22 DOSAGE AND ADMINISTRATION............................................................................. 22 OVERDOSAGE ......... Leggi il documento completo